Current Biotechnology ›› 2024, Vol. 14 ›› Issue (1): 35-41.DOI: 10.19586/j.2095-2341.2023.0107
• Special Forum on Development and Technology of Biologics • Previous Articles Next Articles
Yonghong ZHANG(
), Yanyi LI(
), Ronglin LIU, Na LYU, Weiting ZHANG
Received:2023-09-12
Accepted:2023-10-27
Online:2024-01-25
Published:2024-02-05
Contact:
Yanyi LI
通讯作者:
李岩异
作者简介:张永红 E-mail: yhzh9967@163.com;
CLC Number:
Yonghong ZHANG, Yanyi LI, Ronglin LIU, Na LYU, Weiting ZHANG. Application of IgY in the Field Antiviral Medical[J]. Current Biotechnology, 2024, 14(1): 35-41.
张永红, 李岩异, 刘容麟, 吕娜, 张卫婷. IgY在抗病毒医学领域中的应用[J]. 生物技术进展, 2024, 14(1): 35-41.
| 病原体 | 给药对象及方式 | 作用 | 参考文献 | |
|---|---|---|---|---|
| 流感病毒 | H5N1 | 小鼠,鼻内给药 | 抗流感IgY,通过与病毒表位结合,预防小鼠感染H5N1病毒 | [ |
| H1N1、H3N2、H5N1 | 体外实验 | IgY抗体具有抑制同源毒株的作用 | [ | |
| IBV | 体外实验 | 具有抑制血凝素和神经氨酸酶的活性,并抑制病毒的复制 | [ | |
| 小鼠,鼻内给药 | 预防乙型流感的发生和减缓疾病的进展 | |||
| 轮状病毒 | 轮状病毒患儿,口服 | 减少了口服补液的用量,缩短了病程 | [ | |
| 体外实验 | 特异性IgY能够以剂量依赖的方式抑制细胞损伤和轮状病毒粘附 | [ | ||
| 轮状病毒患儿,口服 | IgY比益生菌能更有效地缩短病程,并显著减少腹泻的频率 | [ | ||
| 轮状病毒患儿,口服 | 抗轮状病毒IgY明显比常规治疗更有效 | [ | ||
| 寨卡病毒 | 体外实验 | 在斑块减少中和实验中,产生的保护作用大于50% | [ | |
| 小鼠,腹腔注射 | 可保护小鼠免受致命的寨卡病毒攻击3周 | |||
| 埃博拉病毒 | 小鼠,腹腔注射 | 高剂量IgY可达到完全的保护作用,而注射低剂量IgY则表现出部分的保护作用 | [ | |
| MERS-CoV | [ | |||
| 体外实验 | [ | |||
| 小鼠,鼻内给药 | ||||
| 小鼠,腹腔注射和口服给药 | [ | |||
| [ | ||||
Table 1 The role of IgY antibody in some viral infectious diseases
| 病原体 | 给药对象及方式 | 作用 | 参考文献 | |
|---|---|---|---|---|
| 流感病毒 | H5N1 | 小鼠,鼻内给药 | 抗流感IgY,通过与病毒表位结合,预防小鼠感染H5N1病毒 | [ |
| H1N1、H3N2、H5N1 | 体外实验 | IgY抗体具有抑制同源毒株的作用 | [ | |
| IBV | 体外实验 | 具有抑制血凝素和神经氨酸酶的活性,并抑制病毒的复制 | [ | |
| 小鼠,鼻内给药 | 预防乙型流感的发生和减缓疾病的进展 | |||
| 轮状病毒 | 轮状病毒患儿,口服 | 减少了口服补液的用量,缩短了病程 | [ | |
| 体外实验 | 特异性IgY能够以剂量依赖的方式抑制细胞损伤和轮状病毒粘附 | [ | ||
| 轮状病毒患儿,口服 | IgY比益生菌能更有效地缩短病程,并显著减少腹泻的频率 | [ | ||
| 轮状病毒患儿,口服 | 抗轮状病毒IgY明显比常规治疗更有效 | [ | ||
| 寨卡病毒 | 体外实验 | 在斑块减少中和实验中,产生的保护作用大于50% | [ | |
| 小鼠,腹腔注射 | 可保护小鼠免受致命的寨卡病毒攻击3周 | |||
| 埃博拉病毒 | 小鼠,腹腔注射 | 高剂量IgY可达到完全的保护作用,而注射低剂量IgY则表现出部分的保护作用 | [ | |
| MERS-CoV | [ | |||
| 体外实验 | [ | |||
| 小鼠,鼻内给药 | ||||
| 小鼠,腹腔注射和口服给药 | [ | |||
| [ | ||||
| 1 | REZAEIFARD M, SOLHI R, MOHAMMADI M, et al.. Production of IgY polyclonal antibody against diphtheria toxin and evaluation of its neutralization effect by Vero cell assay[J/OL]. BMC Biotechnol., 2021, 21(1): 34[2023-11-10]. . |
| 2 | LEÓN-NÚÑEZ D, VIZCAÍNO-LÓPEZ M F, ESCORCIA M, et al.. IgY antibodies as biotherapeutics in biomedicine[J/OL]. Antibod. Basel, 2022, 11(4): 62[2023-11-10]. . |
| 3 | DIAS DA SILVA W, TAMBOURGI D V. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy[J]. Vet. Immunol. Immunopathol., 2010, 135(3-4): 173-180. |
| 4 | LARSSON A, KARLSSON-PARRA A, SJÖQUIST J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors[J]. Clin. Chem., 1991, 37(3): 411-414. |
| 5 | LEE L, SAMARDZIC K, WALLACH M, et al.. Immunoglobulin Y for potential diagnostic and therapeutic applications in infectious diseases[J/OL]. Front. Immunol., 2021, 12: 696003[2023-11-10]. . |
| 6 | SALAZAR G, ZHANG N, FU T M, et al.. Antibody therapies for the prevention and treatment of viral infections[J/OL]. NPJ Vaccines, 2017, 2: 19[2023-11-10]. . |
| 7 | ABBAS A T, EL-KAFRAWY S A, SOHRAB S S, et al.. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections[J]. Hum. Vaccin. Immunother., 2019, 15(1): 264-275. |
| 8 | 林冠峰, 吴英松, 杨懿祺, 等. 抗体药物的发展与应用 [J]. 生物技术进展, 2022, 12(3): 358-365. |
| YANG Y, ZHANG Z, YOU X, et al.. Development and application of monoclonal antibody-based erug[J]. Curr. Biotechnol., 2022, 12(3): 358-365. | |
| 9 | WARR G W, MAGOR K E, HIGGINS D A. IgY: clues to the origins of modern antibodies[J]. Immunol. Today, 1995, 16(8): 392-398. |
| 10 | CHALGHOUMI R, BECKERS Y, PORTETELLE D, et al.. Hen egg yolk antibodies (IgY), production and use for passive immunization against bacterial enteric infections in chicken: a review[J]. Biotechnol. Agron. Soc. Environ., 2009, 13(2): 295-308. |
| 11 | KOVACS-NOLAN J, MINE Y. Egg yolk antibodies for passive immunity[J]. Annu. Rev. Food Sci. Technol., 2012, 3: 163-182. |
| 12 | 李岩异,吕娜,贾思凝,等.体外组装的病毒样颗粒在疫苗和药物递送中的应用[J].生物技术进展,2023,13(2):201-209. |
| LI Y Y, LYU N, JIA S N, et al.. Application of virus like particles assembled in vitro in vaccine and drug delivery[J]. Curr. Biotechnol., 2023, 13(2): 201-209. | |
| 13 | 彭晓燕,陆盼盼,胡祖权.新型冠状病毒RBD蛋白原核表达及多克隆抗体的制备[J].生物技术进展,2023,13(1):102-106. |
| PENG X Y, LU P P, HU Z Q. Prokaryotic expression of the RBD protein of SARS-CoV-2 and its polyclonal antibodies preparation[J]. Curr. Biotechnol., 2023, 13(1): 102-106. | |
| 14 | SVENDSEN BOLLEN L, CROWLEY A, STODULSKI G, et al.. Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants[J]. J. Immunol. Methods, 1996, 191(2): 113-120. |
| 15 | LEIVA C L, GALLARDO M J, CASANOVA N, et al.. IgY-technology (egg yolk antibodies) in human medicine: a review of patents and clinical trials[J/OL]. Int. Immunopharmacol., 2020, 81: 106269[2023-11-20].. |
| 16 | LI X, WANG L, ZHEN Y, et al.. Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review[J/OL]. J. Anim. Sci. Biotechnol., 2015, 6(1): 40[2023-11-20]. . |
| 17 | AHMAD AMRO W, AL-QAISI W, AL-RAZEM F. Production and purification of IgY antibodies from chicken egg yolk[J]. J. Genet. Eng. Biotechnol., 2018, 16(1): 99-103. |
| 18 | 周水娟,郭忠建.双分子荧光互补技术在动物病毒中的研究进展[J].生物技术进展,2022,12(6):825-836. |
| ZHOU S J, GUO Z J. Progress of bimolecular fluorescence complementation technology in animal viruses research[J]. Curr. Biotechnol., 2022, 12(6): 825-836. | |
| 19 | DEMICHELI V, JEFFERSON T, FERRONI E, et al.. Vaccines for preventing influenza in healthy adults[J/OL]. Cochrane Database Syst. Rev., 2018, 2(2): CD001269[2023-11-20]. . |
| 20 | FERGUSON N M, GALVANI A P, BUSH R M. Ecological and immunological determinants of influenza evolution[J]. Nature, 2003, 422(6930): 428-433. |
| 21 | NGUYEN H H, TUMPEY T M, JPARK H, et al.. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice[J/OL]. PLoS ONE, 2010, 5(4): e10152[2023-11-20]. . |
| 22 | WALLACH M G, WEBBY R J, ISLAM F, et al.. Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice[J]. Clin. Vaccine Immunol., 2011, 18(7): 1083-1090. |
| 23 | WEN J, ZHAO S, HE D, et al.. Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus[J]. Antiviral Res., 2012, 93(1): 154-159. |
| 24 | RAHMAN S, HIGO-MORIGUCHI K, HTUN K W, et al.. Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients[J]. Vaccine, 2012, 30(31): 4661-4669. |
| 25 | RAHMAN S, UMEDA K, ICATLO F C, et al.. In vitro cytoprotective effect of infant milk formula fortified with human rotavirus-specific hyperimmune yolk immunoglobulins (IgY)[J]. Food Sci. Biotechnol., 2013, 22(6): 1699-1705. |
| 26 | XIE Y M, GAO S, WANG L Y, et al.. Therapeutic effect of probiotics and oral IgY as supplementary drugs in the treatment of pediatric rotavirus enteritis: a comparative study[J]. Chin. J. Contempor. Ped., 2013, 15(11): 1000-1005. |
| 27 | WANG X, SONG L, TAN W, et al.. Clinical efficacy of oral immunoglobulin Y in infant rotavirus enteritis: systematic review and meta-analysis[J/OL]. Medicine, 2019, 98(27): e16100[2023-11-20]. . |
| 28 | O'DONNELL K L, MEBERG B, SCHILTZ J, et al.. Zika virus-specific IgY results are therapeutic following a lethal zika virus challenge without inducing antibody-dependent enhancement[J/OL]. Viruses, 2019, 11(3): 301[2023-11-20]. . |
| 29 | ZHANG Y, WEI Y, LI Y, et al.. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability[J/OL]. PLoS Negl. Trop. Dis., 2021, 15(3): e0008403[2023-11-20]. . |
| 30 | ABBAS A T, EL-KAFRAWY S A, SOHRAB S S, et al.. Anti-S1 MERS-COV IgY specific antibodies decreases lung inflammation and viral antigen positive cells in the human transgenic mouse model[J/OL]. Vaccines, 2020, 8(4): 634[2023-11-20]. . |
| 31 | BROCATO R, JOSLEYN M, BALLANTYNE J, et al.. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)[J/OL]. PLoS ONE, 2012, 7(4): e35996[2023-11-20]. . |
| 32 | FLIOU J, CHANG C W, JTAILIU J, et al.. Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice[J]. Vaccine, 2010, 28(51): 8189-8196. |
| 33 | FERELLA A, BELLIDO D, CHACANA P, et al.. Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro [J]. Procedia Vaccinol., 2012, 6: 33-38. |
| 34 | 唐颖,武建强.肉苁蓉苯乙醇苷的抗肿瘤作用[J].生物技术进展,2023,13(3):399-405. |
| TANG Y, WU J Q. Anti-tumor effects of phenylethanoid glycosides deprived from Cistanche deserticola [J]. Curr. Biotechnol., 2023, 13(3): 399-405. | |
| 35 | BAILEY J R, BARNES E, COX A L. Approaches, progress, and challenges to hepatitis C vaccine development[J]. Gastroenterology, 2019, 156(2): 418-430. |
| 36 | GUO H, ZHOU E M, SUN Z F, et al.. Immunodominant epitopes mapped by synthetic peptides on the capsid protein of avian hepatitis E virus are non-protective[J]. Viral Immunol., 2008, 21(1): 61-67. |
| 37 | OMATA M, UCHIUMI K, ITO Y, et al.. Duck hepatitis B virus and liver diseases[J]. Gastroenterology, 1983, 85(2): 260-267. |
| 38 | ABOUZID K, NDEBOKO B, DURANTEL S, et al.. Genetic vaccination for production of DNA-designed antibodies specific to Hepadnavirus envelope proteins[J]. Vaccine, 2006, 24(21): 4615-4617. |
| 39 | WIDJAJA I, WANG C, VAN HAPEREN R, et al.. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein[J]. Emerg. Microbes Infect., 2019, 8(1): 516-530. |
| 40 | 高敏宜, 徐笑, 高已雯, 等. 微量元素硒在对抗COVID-19中的作用研究进展[J]. 生物技术进展, 2023, 13(1): 72-76. |
| KAU M, XU X, GAO Y W, et al.. Narrative review on the roles of selenium against COVID-19[J]. Curr. Biotechnol., 2023, 13(1): 72-76. | |
| 41 | ZUMLA A, HUI D S, PERLMAN S. Middle East respiratory syndrome[J]. Lancet, 2015, 386(9997): 995-1007. |
| 42 | SHEAHAN T P, SIMS A C, LEIST S R, et al.. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J/OL]. Nat. Commun., 2020, 11(1): 222[2023-11-20]. . |
| 43 | ZAKI S R, GREER P W, COFFIELD L M, et al.. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease[J]. Am. J. Pathol., 1995, 146(3): 552-579. |
| 44 | CUSTER D M, THOMPSON E, SCHMALJOHN C S, et al.. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine[J]. J. Virol., 2003, 77(18): 9894-9905. |
| 45 | KOMATSU H, SHIMIZU Y, TAKEUCHI Y, et al.. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection[J]. Pediatr. Neurol., 1999, 20(1): 17-23. |
| 46 | STOTT E J, TAYLOR G. Respiratory syncytial virus[J]. Arch. Virol., 1985, 84(1): 1-52. |
| 47 | VAN DER POEL W H, BRAND A, KRAMPS J A, et al.. Respiratory syncytial virus infections in human beings and in cattle[J]. J. Infect., 1994, 29(2): 215-228. |
| [1] | Yuqin BIAN, Keran DONG, Junzi LU, Enming ZHONG, Wanying GU, Jingshu ZHAO, Hongshu SUI. Clinical Progress in Targeted Therapy and Immunotherapy in Breast Cancer [J]. Current Biotechnology, 2025, 15(2): 234-240. |
| [2] | Yan ZENG, Hengcheng ZHU, Kang YANG. The Mechanism of DNASE1L3 in Renal Cell Carcinoma [J]. Current Biotechnology, 2024, 14(3): 486-491. |
| [3] | Lang GAO, Sixue YU, Chunsen YUAN, Zhiwei SHAN, Pengxiang ZHAO. Research Progress of Mucin in Tumor Immunotherapy [J]. Current Biotechnology, 2023, 13(3): 390-398. |
| [4] | Cancan PENG, Huiming WANG. Establishment of Anti-glomerular Basement Membrane Nephritis Model Suitable for Immunotherapy in Rats [J]. Current Biotechnology, 2022, 12(3): 473-478. |
| [5] | Shuxiang LI, Liping AN, Dejuan LIANG, Kaixuan WANG, Jianguo ZHAO. Research Progress on the Treatment of Prion Disease [J]. Current Biotechnology, 2022, 12(2): 229-235. |
| [6] | XUE Wen, JIA Yu, JIANG Yifan, LI Chenxin, WANG Zhiming*. Progress on Immune Checkpoint Inhibitors in Tumor Therapy [J]. Curr. Biotech., 2019, 9(4): 341-349. |
| [7] | LIU Mengyu1, XIE Fei1, ZHANG Xin1, ZHAO Pengxiang1,2*. Review of Immunotherapy for Glioblastoma [J]. Curr. Biotech., 2019, 9(3): 223-230. |
| [8] | LI Geng, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian*. Application of Bispecific Antibody Drugs [J]. Curr. Biotech., 2015, 5(6): 420-424. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||